Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
19.34
-0.49 (-2.47%)
Aug 24, 2026, 10:33 AM EDT - Market open

Avalo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,03732978747191
Market Cap Growth
755.07%323.58%965.79%-84.63%-75.15%-95.47%
Enterprise Value
637218-1-152153
Last Close Price
19.8318.167.439.101209.614895.96

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
18025.135581.57176.293.792.6335.37
PB Ratio
2.343.970.581.00-4.358.27
P/TBV Ratio
2.434.540.63--22.11

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
11244.893699.17--2.8728.36

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.010.010.26-1.981.53
Net Debt / Equity Ratio
-0.89-1.18-1.00-0.75-0.78-0.83
Net Debt / EBITDA Ratio
4.381.353.280.24-0.280.24
Net Debt / FCF Ratio
5.861.902.720.18-0.320.27
Asset Turnover
000.010.070.320.09
Inventory Turnover
----896.212444.83
Quick Ratio
18.947.6019.331.640.682.99
Current Ratio
19.318.1419.951.820.743.11
Return on Equity (ROE)
-36.27%-72.44%-50.06%--684.77%-354.08%
Return on Assets (ROA)
-18.50%-34.12%-29.75%-53.91%-32.95%-82.82%
Return on Invested Capital (ROIC)
-517.90%--6834.61%-359.43%-396.92%-1501.54%
Return on Capital Employed (ROCE)
-19.50%-70.40%-28.40%-143.20%-266.10%-136.20%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-9.43%-23.76%-45.18%-432.43%-87.80%-44.19%
FCF Yield
-6.42%-15.63%-63.10%-422.75%-56.58%-37.19%
Buyback Yield / Dilution
-158.89%-78.82%-2599.19%-608.45%-8.32%-41.86%
SEC Filings: 10-K · 10-Q